Start Date
February 28, 2019
Primary Completion Date
October 1, 2025
Study Completion Date
October 1, 2025
Trabectedin discontinuation
"Patients who did not progressed after 6 cycles of trabectedin will stop the treatment and resume drug in case of progression for other 6 cycles.~The treatment will be resumed again at progression for other 6 cycles and this scheme of treatment will be proposed until progression under trabectedin."
Trabectedin continuation
Patients who did not progressed after 6 cycles of trabectedin will continue the treatment until Progressive Disease or unacceptable toxicity
Fondazione del Piemonte per l'Oncologia IRCC Candiolo, Candiolo
Ospedale Gradenigo, Torino
A.O. SS Antonio e Biagio e Cesare Arrigo, Alessandria
Istituto Clinico Humanitas, Rozzano
Fondazione IRCCS INT Milano, Milan
Istituto Europeo di Oncologia, Milan
Centro di Riferimento Oncologico di Aviano, Aviano
Istituto Ortopedico Rizzoli - Unit of Chemotherapy of Muscoloskeletal Tumors, Bologna
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - IRST, Meldola
Azienda ospedaliero Universitaria Careggi di Firenze, Florence
Policlinico Federico II, Napoli
Irccs Istituto Oncologico Veneto (Iov), Padua
Ospedale Giaccone, Palermo
Istituti Fisioterapici Ospitalieri di Roma, Roma
Policlinico Universitario Campus Biomedico, Roma
Collaborators (1)
PharmaMar
INDUSTRY
Italian Sarcoma Group
NETWORK